AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Massachusetts

H2532

Relative to therapeutic psilocybin treatment centers

Status

Pending

2026 Session

IntroducedFeb 27, 2025 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Lindsay Sabadosa (Democrat)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

For legislation to establish a non profit therapeutic center pilot program offering psilocybin treatment for mental and physical health needs. Public Health.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: malegislature.gov

Legislative history

January 28, 2026
Accompanied a new draft, see H4986
February 27, 2025
Referred
February 27, 2025
Introduced

Loading bill…